Clinical trials
Papillomavirus Vaccines clinical trials
Below are recruiting papillomavirus vaccines clinical trials, each written for real people, not researchers. We’re tracking 28 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05266898RecruitingPhase 4
HPV vaccine response study for people living with HIV
This trial studies how well the Gardasil-9 HPV vaccine triggers the body’s immune response in people living with HIV. It may help doctors understand the best way to protect against HPV-related cancers and infections in this population.
New Orleans, LouisianaAges 18–65 - NCT07266857Recruiting
Study on HPV vaccine education in middle schools
This trial tests if an educational program called e-Bug can increase HPV vaccination rates. It uses only anonymous data from schools, so no individual enrollment is needed.
Nice, Alpes MaritimesAges Any age - NCT07248904Recruiting
HPV education study for first-year nursing students
This study tests whether a special education program based on the transtheoretical model improves nursing students' knowledge about HPV, their health beliefs, and their intentions to get vaccinated. It aims to help students make informed decisions about HPV prevention.
Adana, CUKUROVAAges 18 years+ - NCT05985681RecruitingPhase 1
Vaccine to prevent HPV-related cancers
This trial tests a new vaccine (RG1-VLP) designed to prevent HPV-related cancers. It is for healthy women who have not been vaccinated against HPV before and are willing to receive three doses of the vaccine over several months.
Birmingham, AlabamaAges 18–60 - NCT05625633RecruitingPhase 2/Phase 3
HPV vaccine vs placebo for stubborn skin warts
This study tests whether an HPV vaccine can help shrink or clear cutaneous (skin) warts that have not responded to prior treatments. Participants get the study vaccine or a placebo to compare results and safety.
Salt Lake City, UtahAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT07301905Recruiting
HPV vaccine study for parents in Flint, MI
This study tests a culturally tailored health message to see if it helps parents feel more open to the HPV vaccine for their daughters. It focuses on families in Flint whose daughters have not yet received the vaccine.
Flint, MichiganAges 18 years+ - NCT05262010RecruitingPhase 3
HPV vaccine study for Chinese women, ages 9–45
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
Hechi, GuangxiAges 18–45 - NCT06535139Recruiting
HPV Vaccine Study for Rural Kids 8 to 12
This study aims to help prevent HPV-related cancers by increasing HPV vaccination rates in rural areas. It is for parents of 8- to 12-year-olds who have not yet completed the two-dose HPV vaccine series.
Gainesville, FloridaAges 8–99 - NCT06808776Recruiting
Stories to prevent HPV cancers
This trial tests if sharing stories can help parents decide to get their child the HPV vaccine. It is for parents of children ages 9 to 12 who have not yet started the HPV shot series.
Hershey, PennsylvaniaAges 18 years+ - NCT06624839RecruitingPhase 2
HPV vaccine study for people with and without HIV
This study tests how well the Gardasil 9 HPV vaccine works in people assigned male at birth, including those with HIV and those taking hormone therapy. Results could help protect against HPV-related cancers.
Washington D.C., District of ColumbiaAges 18–70 - NCT05365048Recruiting
Promoting HPV vaccine visits in kids ages 9–12
This study looks at whether getting a provider recommendation helps more parents bring children ages 9–12 in for HPV vaccination. It may help increase vaccination uptake in pediatric clinics.
Pasadena, CaliforniaAges 21–70 - NCT06658405RecruitingPhase 2
HPV vaccine after cervical lesion treatment
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
LilleAges 45 years+ - NCT06793410RecruitingPhase 2
HPV vaccine after stem cell transplant
This trial tests if the HPV vaccine works safely in people who received a stem cell transplant from a donor. It may help prevent HPV-related cancers in transplant survivors.
Lund, Region SkåneAges 18–45 - NCT05672927RecruitingPhase 4
Comparing HPV vaccine schedules: 2 doses vs 3 doses
This study compares how well your immune system responds to an HPV vaccine given as either 2 doses or 3 doses in people ages 27–45 who have never had the HPV vaccine. It may help improve HPV prevention strategies and guide the best dose schedule for adults.
Galveston, TexasAges 27–45 - NCT06686043RecruitingPhase 2
HPV vaccine, imiquimod, and metformin for advanced cervical or vulvar cancer
This trial tests a combination of an HPV vaccine, an immune cream (imiquimod), and a diabetes drug (metformin) together with standard chemoradiation. The goal is to see if this mix helps treat advanced cervical, vaginal, or vulvar cancers better than standard care alone.
Houston, TexasAges 18–64 - NCT07104240Recruiting
Improving HPV vaccination for preteens ages 9-12
This study tests a program designed to help primary care practices increase HPV vaccination rates among adolescents aged 9 to 12 who haven't yet been vaccinated. It aims to find out if providing practices with resources and support can lead to more kids getting the HPV vaccine.
Atlanta, GeorgiaAges 9 years+ - NCT06995157Recruiting
HPV infections and vaccine attitudes in Slovenian women
This observational study looks at HPV infections and women's views about the HPV vaccine in Slovenia. It aims to understand the characteristics of HPV infections and attitudes toward vaccination after the vaccine became available.
Ljubljana, Municipality of DomžaleAges Up to 35 years - NCT07668271RecruitingPhase 4
HPV 9-valent vaccine lot consistency trial for women
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
Zhangping, FujianAges 18–30 - NCT06007092RecruitingPhase 1/Phase 2
HPV vaccine trial for oropharyngeal cancer patients
This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.
VillejuifAges 18 years+ - NCT06598475Recruiting
Improving HPV vaccination in Latino teens at health centers
This trial tests a program to help community health centers recommend and boost HPV vaccination rates among Latino adolescents aged 11-12. It aims to support health care providers and staff with education and resources.
Houston, TexasAges 11–17 - NCT06926062Recruiting
Improving HPV vaccine communication in pharmacies
This study looks at whether training pharmacy staff in communication and vaccination workflows can improve HPV vaccine recommendations and uptake. If you are a parent or guardian of a child aged 9–17 who has not yet completed the HPV vaccine series, you may be eligible to participate.
University Park, PennsylvaniaAges 18 years+ - NCT06650956Recruiting
HPV vaccine and health education for teens in Laos
This trial offers HPV vaccination and sexual health education to 10-13 year old students and out-of-school youth in Laos. It aims to improve health knowledge and vaccination rates.
Muang Sing, ProvinceAges 10–13 - NCT04131413RecruitingPhase 1
HPV vaccine given through the skin for HPV16 cervical disease
This early-phase study tests a vaccine designed to help your immune system fight HPV16, a type of human papillomavirus linked to abnormal cells in the cervix. You may or may not be living with HIV, and the team will check safety and immune response after giving the vaccine in a specific way.
Birmingham, AlabamaAges 19 years+
Hear when a new Papillomavirus Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for papillomavirus vaccines?
- Yes. Clin2 currently lists 28 recruiting papillomavirus vaccines studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a papillomavirus vaccines trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a papillomavirus vaccines trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.